Background Critically ill patients often require emergency intubation. The use of etomidate as the sedative agent in this context has been challenged because it might cause a reversible adrenal insuffi ciency, potentially associated with increased in-hospital morbidity. We compared early and 28-day morbidity after a single dose of etomidate or ketamine used for emergency endotracheal intubation of critically ill patients.
Introduction
Critically ill patients often require emergency orotracheal intubation for airway control. Rapid sequence intubation with administration of a sedative and a paralytic agent is common. Etomidate is the sedative-hypnotic drug that is most often used in rapid sequence intubation, but its use has been challenged because it can cause a reversible adrenal insuffi ciency by dose-dependent inhibition of 11β-hydroxylase. 1, 2 Several studies have suggested an association between the use of etomidate and the occurrence of adrenal in suffi ciency and increased morbidity in critically ill or injured patients, particularly in those with sepsis. [3] [4] [5] [6] [7] [8] Because adrenal insuffi ciency when a patient is critically ill can increase the risk of death, several investigators have advised against the use of etomidate, even as a single bolus. 9 However, no causal link has been established between its use and an increase in morbidity and mortality.
Etomidate's haemodynamic tolerance, even in patients with shock, and the excellent intubation conditions provided have to be weighed against potential adverse eff ects, including adrenal insuffi ciency. 10 A possible alternative to etomidate is ketamine, which is not known to inhibit the adrenal axis. The aim of this randomised controlled study was to compare early and 28-day morbidity after a single dose of etomidate or ketamine used for emergency endotracheal intubation of critically ill patients.
Methods

Study setting and patients
This prospective, randomised, controlled, single-blind (caregiver) trial was undertaken from April 25, 2007 , to Feb 27, 2008 , by 12 emergency medical services or emergency departments and 65 intensive care units in France. The emergency medical services are ambulance base stations equipped with one or more mobile intensive care units, consisting of an ambulance driver, a nurse, and a senior emergency physician as the minimum team. 11 Patients who were 18 years or older and who needed sedation for emergency intubation were prospectively enrolled in the study. Exclusion criteria were cardiac arrest; contraindications to succinylcholine, ketamine, or etomidate; or known pregnancy. As specifi ed in the analysis plan, we excluded, after randomisation, patients who were discharged alive from the intensive care unit within 3 days, to retain only the most severely ill patients. We also excluded after randomisation patients who died before reaching the hospital because their death could not reasonably have been attributed to sedative use. The modifi ed intention-to-treat analysis (mITT population) included all other randomised patients.
The study was approved by Aulnay Hospital's Ethics Committee for the Protection of Persons (number AOM06103). Informed consent was waived at randomisation because patients needed urgent intubation. Whenever a patient was included without written informed consent, such consent was promptly sought, according to the French Law of Ethics, from a legally authorised representative and subsequently from the patient.
Procedures
Patients were randomly assigned in a 1:1 ratio to either etomidate (Lipuro, B Braun Medical, Boulogne, France) administered as a 0·3 mg/kg intravenous bolus, or to ketamine (Ketalar, Panpharma, Fougères, France) administered as a 2 mg/kg intravenous bolus. Randomisation was done in blocks of four by a computerised random-number generator list provided by a statistician who was not involved in determination of patient eligibility, drug administration, or outcome assessment. In every centre, the study drug was sealed in sequentially numbered, identical boxes containing the entire treatment for each patient. The emergency physician enrolling patients was aware of study group assignment. However, nurses and intensivists in the intensive care unit were masked to the treatment assigned because it was not specifi ed on the patient's medical record or conveyed in verbal or written reports. Additionally, none of the emergency physicians enrolling patients were members of the staff in the intensive care unit, and they had no infl uence on the management of the patients while they were in intensive care.
Succinylcholine (Celocurine, Orion Pharma, Levallois Perret, France) was given immediately after the sedative as a 1 mg/kg intravenous bolus. After confi rmation of intubation and tube placement, continuous sedation was initiated by use of a standardised protocol with midazolam (0·1 mg/kg/h) combined with fentanyl (2-5 μg/kg/h) or sufentanil (0·2-0·5 μg/kg/h).
Organ system function was defi ned for each of the six major organ systems with the sequential organ failure assessment (SOFA) with a scale ranging from 0 to 4 for each organ system, for an aggregate score of 0-24, with high scores indicating severe organ dysfunction. 12 The Glasgow coma score was recorded immediately before rapid sequence intubation to assess the neurological component of the SOFA at admission. The other components of the SOFA were computed with the worst values recorded for corresponding variables within the preceding 24 h. The maximum SOFA score was defi ned by the sum of the maximum values for each organ system during the follow-up period. 13 We assessed organ dysfunction and failure occurring after admission to the intensive care unit (Δ-SOFA) by computing the maximum SOFA score minus the admission SOFA score. 14 We defi ned adrenal insuffi ciency as a random cortisol concentration of less than 276 nmol/L or a diff erence from baseline concentration of less than 250 nmol/L at 30 min or 60 min after adrenocorticotropin hormone stimulation test. 15 A patient was defi ned as a non-responder if the increase in cortisol did not exceed 250 nmol/L at these times. 16 We computed the intubation diffi culty score-a measure of intubation diffi culty-as the sum of seven variables (number of attempts, number of operators, number of alternative techniques, glottic visualisation, lifting force, use of external laryngeal pressure, and vocal cords position). 17 A value greater than 5 (on a scale ranging from 0: easy intubation; to infi nity: intubation impossible) is synonymous to diffi cult intubation. 17 For the clinical assessment, we recorded general characteristics of the patient including demographics, presenting symptoms, and fi nal diagnoses; severity of For laboratory variables we recorded haematological and chemistry data, and arterial blood gas determinations. When recommended by the physician, a short adrenocorticotropin hormone test was done during the 48 h after admission, with blood samples taken immediately before and 30-60 min after an intravenous bolus of 0·25 mg tetracosactrin (Novartis, Stein, Switzerland).
During the 28-day period after randomisation (follow-up period), we collected data for vital signs, results from laboratory tests, and any major interventions done. We recorded mortality at 28 days and at discharge from intensive care unit. Throughout the study, a Data Safety Monitoring Board monitored patients' safety every 3 months.
The primary endpoint was the maximum SOFA score during the fi rst 3 days in the intensive care unit. The SOFA score during the fi rst few days of admission was chosen because adrenal insuffi ciency due to etomidate is reversible and lasts up to 48 h, 7 and because it is a reliable prognostic indicator. 13, 18 Secondary endpoints were Δ-SOFA score (maximum score minus admission score), 28-day all-cause mortality, days free from intensive care unit, and organ support-free days (mechanical ventilation and vasopressor) during the 28-day follow-up. Safety was assessed by recording serious adverse events and particularly the intubation diffi culty score, the absolute diff erence in arterial blood pressure before and after intubation, oxygen saturation, and cardiac arrest during intubation.
Statistical analysis
We defi ned a priori that the combined subgroup of patients with a fi nal diagnosis of confi rmed sepsis or trauma was of major clinical interest. The sample size calculation was therefore designed to provide a suffi cient power for analysing this subgroup. On the basis of Moreno and colleagues' study, 14 the relevant diff erence in maximum SOFA score to be detected between the two treatment groups was considered equal to 2 points. With an SD of 4, 14 a sample size of 130 patients allowed an 80% power to detect this diff erence with a two-sided t test with type-I error of 0·05. Since we analysed the mITT population for the primary analysis (ie, we excluded from the analysis randomised patients who died before reaching hospital and those discharged from the intensive care unit within 3 days), and we anticipated that about 30% of patients would die before reaching hospital or be discharged alive before 3 days, we determined that 200 patients should be included in the subgroup of interest, allowing for about 5% of patients with important data missing. After considering that this subgroup would account for about 30% of the total randomised population, we decided to recruit a total population of 650 patients.
Results are given as mean (SD) for normally distributed variables, as medians (IQR) for non Gaussian quantitative variables, and as numbers and percentages (95% CI) for categorical variables. After checking normality of the distribution, we compared the maximum SOFA scores in the two groups with generalised linear models adjusted for centre (including a group×centre interaction in the models). Since we excluded patients for the mITT analysis and had thus possibly interfered with the randomisation, we decided a posteriori to make a complementary sensitivity analysis adjusted for age, simplifi ed acute physiology score II, and sex.
For secondary endpoints, the two groups were compared by student's t test or Wilcoxon rank-sum test for normally or non-normally distributed quantitative variables, respectively. We compared categorical data with either the χ² or Fisher's exact test, as appropriate. Odds ratios for death and their 95% CI were estimated in the mITT population and in the predefi ned subgroups. Time to event within the 28-day follow-up of the study was described by survival curves with Kaplan-Meier's method, and the hazard ratio with 95% CI was estimated between the two groups. Patients who died during the follow-up period before being weaned from catecholamine support or mechanical ventilation were regarded as not having been weaned within the 28-day follow-up.
All statistical tests were two-sided. The chosen type-1 error rate was a p value less than 0·05, except when testing the subgroup of patients with sepsis or trauma for which a Bonferroni's adjustment for multiplicity was used (p<0·025). Analyses were done with SAS statistical software (version 9.1.3).
This trial is registered with ClinicalTrials.gov, number NCT00440102.
Role of the funding source
The funding source had no role in the study design, data collection, data analysis, data interpretation, or writing the report. All authors had full access to all the data in the study, and all agreed to submit for publication. SOFA max =the maximum value of the sequential organ failure assessment (SOFA) score during the fi rst 3 days in intensive care. ICU=intensive care unit. IDS=intubation diffi culty score. SpO 2 =pulse oxygen saturation. *Δ-SOFA= SOFA max -SOFA(admission). †Bootstrap CI for median diff erence. ‡Diffi cult intubation is defi ned as IDS>5. §Change in arterial systolic blood pressure equals pre-intubation minus post-intubation arterial systolic blood pressure. ¶Change in arterial diastolic blood pressure equals pre-intubation minus post-intubation arterial diastolic blood pressure. ||Change in SpO 2 equals post-intubation minus pre-intubation SpO 2 .
Table 2: Primary and secondary endpoints and intubation condition for study patients
Results Figure 1 shows the trial profi le. Of the 689 patients assessed for eligibility, 655 were consecutively and randomly assigned to treatment and 650 were analysed (ITT population; fi gure 1). All allocated treatments were delivered to the randomised patients. The mITT analysis was undertaken in 469 patients (n=234 in etomidate group and n=235 in ketamine group). The number of patients who died before reaching hospital or who were discharged alive before 3 days from the intensive care unit was similar in the two groups (fi gure 1). Baseline characteristics of the patients were similar in both groups (table 1). Coma was the main reason for intubation. Trauma was the fi nal diagnosis in 104 (22%) patients and sepsis in 76 (16%) (table 1). Other diagnoses included stroke (50 patients in etomidate group vs 54 in ketamine group), drug poisoning (41 vs 51), cardiogenic shock (21 vs 28), acute respiratory failure (19 vs 15), or various others (fi ve vs fi ve).
The maximum SOFA score did not diff er signifi cantly between the two groups (table 2  table 2 ). We did not record any centre eff ect (p=0·30) nor interaction between the primary endpoint and centre (p=0·78). The Δ-SOFA score from maximum to admission did not diff er signifi cantly between the two groups (table 2) . Furthermore, none of the six components of the SOFA score diff ered signifi cantly between the etomidate and the ketamine groups (data not shown). In the sensitivity analysis adjusted for age, simplifi ed acute physiology score II, and sex, the diff erence between the two groups remained non-signifi cant (0·6 [95% CI 0·0-1·3]; p=0·064).
We detected no statistical diff erence between the two groups in secondary outcome measures-ie, in diffi culty of intubation or in early complications after intubation (table 2) . Furthermore, 28-day mortality, catecholaminefree days at day 28, duration of catecholamine weaning, per cent age of patients needing catecholamine, mechanical ventilation-free days at day 28, duration of weaning from the ventilator, and length of stay in the intensive care unit did not diff er between groups (table 2 and fi gure 2 fi gure 2). We recorded no serious adverse events with either study drug. In an ITT analysis including 650 patients, we recorded no signifi cant diff erence between the two groups for either maximum SOFA score or 28-day mortality (mean diff erence 0·4 [95% CI -0·2 to 1·0], p=0·20; and 2% [-6 to 10], p=0·54, respectively).
We assessed adrenal axis function in 232 patients (116 per group). Basal cortisol was signifi cantly lower in the etomidate group, and the percentage of non-responders to the adrenocorticotropin hormone stimulation test was signifi cantly higher than in the ketamine group (OR 5·8 [95% CI 3·2-10·5]; table 3). The percentage of patients with adrenal insuffi ciency was signifi cantly higher in the etomidate group than in the ketamine group (OR 6·7, 3·5-12·7; We recorded no signifi cant diff erences in maximum SOFA score nor mortality between the etomidate and ketamine recipients in the subgroup analysis, which included patients with trauma or sepsis (n=180), sepsis patients only (n=76), trauma patients only (n=104), or patients with neither sepsis nor trauma (n=289; fi gure 3).
Discussion
Our study shows that one etomidate bolus is not associated with a signifi cant increase in morbidity or mortality compared with ketamine in patients admitted to the intensive care unit. The maximum SOFA score did not diff er signifi cantly between the two drugs in the subgroup of patients having sepsis or trauma. However, for the subgroup of septic patients (n=76), the small number of patients might account for the absence of signifi cant diff erence. The mortality rate at day 28 in this subgroup did not diff er between the treatment groups.
An association between the administration of etomidate and an increased mortality of patients with sepsis has been suggested previously. In a retrospective study of children with meningococcal sepsis or shock, 7 mortality rate was 30% in patients who received etomidate versus 12% in those who did not, but the diff erence was not signifi cant (OR 3·1 [95% CI 0·3-79·3]). In a post-hoc analysis of the Corticus study undertaken in patients with severe sepsis, 16 the 28-day mortality rate was signifi cantly higher in patients who received etomidate than in those who did not (p=0·03). The investigators, however, did not draw any cause and eff ect conclusion, presumably because of the lack of randomisation to sedative agents.
By contrast with the substantial increase in mortality reported by Ledingham and Watts, 3 etomidate did not aff ect outcome in trauma patients in our study. This discrepancy between the two studies is probably related to the duration of etomidate administration: one bolus in our study versus prolonged sedation in Ledingham and Watts' study. Hildreth and co-workers 8 reported increased use of blood products, ventilator days, and days in intensive care in trauma patients randomly assigned to etomidate (n=18) versus midazolam (n=12), but reported no diff erence in mortality. However, interpretation of this study is diffi cult because half of the eligible patients were excluded, with 11 of 31 patients having received etomidate.
Although adrenal axis dysfunction arises to some extent after etomidate use for rapid sequence intubation, the eff ect of such adrenal suppression on patients' outcome remains debated. Studies have reported increased mortality in non-responders to the adrenocorticotropin hormone stimulation test and in patients with adrenal insuffi ciency. 4, 5 One bolus of etomidate decreases cortisol secretion, which contributed to the increased morbidity and mortality reported in several studies. 6, 7, 16 However, these fi ndings have not been confi rmed by other investigators. 19, 20 Clearly, the results of these studies could be biased owing to the presence of multiple confounding factors.
Our study confi rms the fi nding of others that etomidate aff ects the adrenal axis: according to our criteria, more than four-fi fths of etomidate recipients had adrenal insuffi ciency and were non-responders to the adreno corticotropin hormone stimulation test. About half of patients given ketamine also had adrenal insuffi ciency, which emphasises that critical illness per se aff ects adrenal function. In one study, more than 30% of non-responders had not been exposed to 22 Adrenal insuffi ciency is probably associated with increased mortality in critically ill patients, including those with sepsis; however, whether the adrenal axis suppression and mortality are the result of some underlying process, or whether the adrenal axis suppression causes death, has never been established. Among established indepen dent predictors of low cortisol response to adrenocortico tropin hormone stimulation are a low pH or bicarbonate and platelet count, disease severity, and organ failure. 23 Fentanyl or sufentanil infusion can also modify cortisol concentrations. 24, 25 However, these factors should not aff ect the results of our study since both patient groups received the same type of continuous sedation (fentanyl or sufentanil combined with midazolam). Etomidate is the sedative-hypnotic drug most often used by emergency physicians for rapid sequence intubation, and is the drug of choice for patients who are haemodynamically unstable. 26 Use of ketamine instead of etomidate might have drawn attention to potential adverse eff ects of the use of ketamine during the intubation procedure. 10 The most common side-eff ects of ketamine are psychodysleptic eff ects, but they could not be observed because, unlike in an operating theatre, patients are not awakened until several hours after intubation. We noted no diff erence between the sedative drugs tested in our study on the ease of intubation, probably because intubation conditions depend mostly on the muscle relaxant eff ects of succinylcholine. Accordingly, Sivilotti and Ducharme 27 reported no signifi cant diff erence in the overall successful intubation in a comparison of three hypnotic drugs.
With regard to the strengths and limitations of our study, we have confi rmed the appropriateness of the choice of the maximum SOFA score as the primary endpoint. There is an established relation between the maximum SOFA score and Δ-SOFA score (from maximum to admission) and mortality in patients who are critically ill. 13 Moreover, measurement of the SOFA score has good reliability and accuracy among intensivists. 28 These scores have shown its usefulness in the assessment of in-hospital morbidity in seriously ill patients. 13, 29, 30 However, our study might not have had suffi cient power to show a signifi cant increase in morbidity related to the use of etomidate in patients with sepsis. Our failure to enrol and analyse a larger number of patients with sepsis could have led to a type-II error for this group. A future study should be based on patients with sepsis only, since the controversy regarding the use of etomidate focuses on these patients. We felt that patients admitted with trauma were important to study as well because of suggestions from recent reports that etomidate might be harmful to this group of patients. 8 In conclusion, our results show that ketamine is a safe and valuable alternative to etomidate for intubation in critically ill patients, particularly in septic patients.
